Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

PepGen advances PGN-EDODM1 to highest dose; November readout and 2027 catalysts

Aug 6, 2026, 7:40 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive DSMB guidance and imminent data readouts reduce clinical and funding uncertainty, potentially lifting the stock on favorable results and progress toward EOP2 discussions.

AI summary

What happened, with direct paths to the underlying reporting

PepGen disclosed Q2 highlights with DSMB guidance to push PGN-EDODM1 to 12.5 mg/kg in FREEDOM2-DM1 and to escalate the FREEDOM2 open-label extension to 10 mg/kg. The 10 mg/kg MAD cohort data is due in November, with 12.5 mg/kg results anticipated in 1H 2027. A cash balance of $117.2M supports operations into late 2027 amid ongoing regulatory and clinical milestones.

DSMB recommends advancing FREEDOM2-DM1 to 12.5 mg/kg; OLE to 10 mg/kg.
10 mg/kg MAD cohort fully enrolled; data expected in November.
12.5 mg/kg FREEDOM2 results expected in 1H 2027.
Cash and equivalents totaled $117.2M as of 6/30/2026; runway into Q4 2027.
PepGen remains focused on FREEDOM2/DM1; near-term catalysts could lift valuation.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

PepGen advances PGN-EDODM1 to highest dose; November readout and 2027 catalysts

Upcoming Trial Results and Conference Data Crucial for PepGen's PEPG Stock

PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles

PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate

PepGen to discontinue development of experimental Duchenne therapy; shares drop